These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36383708)

  • 1. Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
    Klein LJ; Abdullahi SU; Gambo S; Stallings VA; Acra S; Rodeghier M; DeBaun MR
    Blood Adv; 2023 Jun; 7(11):2339-2346. PubMed ID: 36383708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
    Abdullahi SU; Jibir BW; Bello-Manga H; Gambo S; Inuwa H; Tijjani AG; Idris N; Galadanci A; Hikima MS; Galadanci N; Borodo A; Tabari AM; Haliru L; Suleiman A; Ibrahim J; Greene BC; Ghafuri DL; Rodeghier M; Slaughter JC; Kirkham FJ; Neville K; Kassim A; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
    Lancet Haematol; 2022 Jan; 9(1):e26-e37. PubMed ID: 34971579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study.
    Estepp JH; Cong Z; Agodoa I; Kang G; Ding J; McCarville MB; Hankins JS; Wang WC
    Br J Haematol; 2021 Jul; 194(2):463-468. PubMed ID: 34131902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
    Alvarez O; Yovetich NA; Scott JP; Owen W; Miller ST; Schultz W; Lockhart A; Aygun B; Flanagan J; Bonner M; Mueller BU; Ware RE;
    Am J Hematol; 2013 Nov; 88(11):932-8. PubMed ID: 23861242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa.
    Smart LR; Ambrose EE; Balyorugulu G; Songoro P; Shabani I; Komba P; Charles M; Howard TA; McElhinney KE; O'Hara SM; Odame J; Nakafeero M; Adams J; Stuber SE; Lane A; Latham TS; Makubi AN; Ware RE
    Acta Haematol; 2023; 146(2):95-105. PubMed ID: 35977532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
    Ofakunrin AOD; Oguche S; Adekola K; Okpe ES; Afolaranmi TO; Diaku-Akinwumi IN; Zoakah AI; Sagay AS
    J Trop Pediatr; 2020 Jun; 66(3):290-298. PubMed ID: 31608959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.
    Ambrose EE; Latham TS; Songoro P; Charles M; Lane AC; Stuber SE; Makubi AN; Ware RE; Smart LR
    Lancet Haematol; 2023 Apr; 10(4):e261-e271. PubMed ID: 36870358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia.
    Ghafuri DL; Chaturvedi S; Rodeghier M; Stimpson SJ; McClain B; Byrd J; DeBaun MR
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
    Galadanci AA; Galadanci NA; Jibir BW; Abdullahi SU; Idris N; Gambo S; Ali Abubakar SA; Kabo NA; Bello-Manga H; Haliru L; Bashir I; Aliyu MH; Galadanci JA; DeBaun MR
    Am J Hematol; 2019 Nov; 94(11):E305-E307. PubMed ID: 31423630
    [No Abstract]   [Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of sickle cell disease with anthropometric indices among under-five children: evidence from 2018 Nigeria Demographic and Health Survey.
    Islam MR; Moinuddin M; Ahmed A; Rahman SM
    BMC Med; 2021 Jan; 19(1):5. PubMed ID: 33446196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD003146. PubMed ID: 28094851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Kohli R; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003146. PubMed ID: 32716555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial.
    Helton KJ; Adams RJ; Kesler KL; Lockhart A; Aygun B; Driscoll C; Heeney MM; Jackson SM; Krishnamurti L; Miller ST; Sarnaik SA; Schultz WH; Ware RE;
    Blood; 2014 Aug; 124(6):891-8. PubMed ID: 24914136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burden of neurological and neurocognitive impairment in pediatric sickle cell anemia in Uganda (BRAIN SAFE): a cross-sectional study.
    Green NS; Munube D; Bangirana P; Buluma LR; Kebirungi B; Opoka R; Mupere E; Kasirye P; Kiguli S; Birabwa A; Kawooya MS; Lubowa SK; Sekibira R; Kayongo E; Hume H; Elkind M; Peng W; Li G; Rosano C; LaRussa P; Minja FJ; Boehme A; Idro R
    BMC Pediatr; 2019 Oct; 19(1):381. PubMed ID: 31651270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia.
    Zimmerman SA; Schultz WH; Burgett S; Mortier NA; Ware RE
    Blood; 2007 Aug; 110(3):1043-7. PubMed ID: 17429008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
    Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
    Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Associated With Child Stunting, Wasting, and Underweight in 35 Low- and Middle-Income Countries.
    Li Z; Kim R; Vollmer S; Subramanian SV
    JAMA Netw Open; 2020 Apr; 3(4):e203386. PubMed ID: 32320037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.